Sickle cell anemia is the world's most common genetic disorder. It causes the red blood pigment hemoglobin to crystallize, ...

A new obesity drug that Eli Lilly is researching but hasn't approved is turning up online, even though it's not supposed to be available.

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

CNW/ - Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant® for ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to ...

Jan 12 () - Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro ...